文献速递皮肤肿瘤药疹与重症皮肤不良反应

靶向抗癌药治疗患者的色素改变:系统综述与荟萃分析

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
PubMed 文献 · J Am Acad Dermatol · 2017-09-14

该研究通过系统综述与荟萃分析,纳入36项临床试验共8052例患者,评估靶向抗癌药所致色素改变的发生率与风险。结果显示皮肤和毛发全级别色素改变总体发生率分别为17.7%和21.5%,相对风险分别为93.7和20.1。53篇病例报告/系列(75例)中,EGFR和BCR-ABL抑制剂是最常见致病药物。

要点

  • 靶向抗癌药治疗中皮肤色素改变总体发生率为17.7%,毛发为21.5%。
  • 皮肤和毛发色素改变的相对风险分别高达93.7和20.1。
  • EGFR与BCR-ABL抑制剂是病例报告中最常见的致病药物。

核心结论

  • 靶向抗癌药治疗期间发生色素改变的风险显著,需进行适当咨询和管理以减轻心理社会损害和生活质量下降。

研究设计与样本

  • 系统综述与荟萃分析,纳入36项临床试验共8052例患者,并回顾53篇病例报告/系列(75例患者)。

主要发现

  • 靶向抗癌药所致皮肤全级别色素改变总体发生率为17.7%(95%CI 11.9-25.4)。
  • 毛发全级别色素改变总体发生率为21.5%(95%CI 14.9-30.1)。
  • 皮肤全级别色素改变的相对风险为93.7(95%CI 5.86-1497.164)。
  • 毛发全级别色素改变的相对风险为20.1(95%CI 8.35-48.248)。
  • 53篇病例报告/系列(75例患者)中,EGFR和BCR-ABL抑制剂是最常见致病药物。

临床怎么用

  • 对接受靶向抗癌药治疗的患者应进行色素改变风险咨询和适当管理,以减少心理社会损害和生活质量下降。

局限性

  • 可能存在漏报以及肿瘤科医生报告这些事件的变异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The discovery of signaling networks that drive oncogenic processes has led to the development of targeted anticancer agents. The burden of pigmentary adverse events from these drugs is unknown. OBJECTIVE: To conduct a systematic review and meta-analysis of published clinical trials and determine the incidence and risk of development of targeted therapy-induced pigmentary changes. METHODS: A comprehensive search was conducted to identify studies reporting targeted therapy-induced pigmentary changes. The incidence and relative risk were calculated. Case reports and series were reviewed to understand clinical characteristics. RESULTS: A total of 8052 patients from 36 clinical trials were included. The calculated overall incidences of targeted cancer therapy-induced all-grade pigmentary changes in the skin and hair were 17.7% (95% confidence interval [CI], 11.9-25.4) and 21.5% (95% CI, 14.9-30.1), respectively. The relative risk of all-grade pigmentary changes of skin and hair were 93.7 (95% CI, 5.86-1497.164) and 20.1 (95% CI, 8.35-48.248). Across 53 case reports/series (N = 75 patients), epidermal growth factor receptor and breakpoint cluster region-abelson inhibitors were the most common offending agents. LIMITATIONS: Potential under-reporting and variability in oncologists reporting these events. CONCLUSION: There is a significant risk of development of pigmentary changes during treatment with targeted anticancer therapies. Appropriate counseling and management are critical to minimize psychosocial impairment and deterioration in quality of life.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Dai J, Belum VR, Wu S, et al. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. J Am Acad Dermatol. 2017. PMID: 28918974. doi:10.1016/j.jaad.2017.06.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。